These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 21093951)

  • 1. The GAPs between hepatocellular carcinoma and RAS.
    Guachalla LM; Rudolph KL
    J Hepatol; 2011 Feb; 54(2):191-2. PubMed ID: 21093951
    [No Abstract]   [Full Text] [Related]  

  • 2. Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer.
    Calvisi DF; Ladu S; Conner EA; Seo D; Hsieh JT; Factor VM; Thorgeirsson SS
    J Hepatol; 2011 Feb; 54(2):311-9. PubMed ID: 21067840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of the Ras regulator RASAL1: another route to Ras activation in colorectal cancer.
    Bernards A; Settleman J
    Gastroenterology; 2009 Jan; 136(1):46-8. PubMed ID: 19041648
    [No Abstract]   [Full Text] [Related]  

  • 4. [Liver and hereditary alpha 1-antitrypsin deficiency].
    Feldmann G
    Gastroenterol Clin Biol; 1993; 17(2):83-93. PubMed ID: 8388836
    [No Abstract]   [Full Text] [Related]  

  • 5. Hepatocellular carcinoma: genome-scale metabolic models for hepatocellular carcinoma.
    Pinyol R; Llovet JM
    Nat Rev Gastroenterol Hepatol; 2014 Jun; 11(6):336-7. PubMed ID: 24840704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is family history of liver cancer a risk factor for hepatocellular carcinoma?
    Volk ML; Lok AS
    J Hepatol; 2009 Feb; 50(2):247-8. PubMed ID: 19070916
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeting chemokines as a therapeutic option for hepatocellular carcinoma: a reality or just a fantasy?
    Yu J
    J Gastroenterol Hepatol; 2007 May; 22(5):611-2. PubMed ID: 17444845
    [No Abstract]   [Full Text] [Related]  

  • 8. [The inhibitory effect of RNA interference on STAT3 expression in liver cancer cell line SMMC7721].
    Liao WJ; Mei MH; Qin LL; Chen Q; Yuan SG; Liu J
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2011 Jun; 27(6):615-7. PubMed ID: 21651859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Molecular biology of liver neoplasms].
    Toda G
    Nihon Naika Gakkai Zasshi; 1991 Oct; 80(10):1687-93. PubMed ID: 1663536
    [No Abstract]   [Full Text] [Related]  

  • 10. [Hepatocellular carcinoma: molecular pathogenesis and novel targets for therapy].
    Marquardt JU; Galle PR; Teufel A
    Dtsch Med Wochenschr; 2012 Apr; 137(16):855-60. PubMed ID: 22495921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ras oncogene p21 expression in hepatocellular carcinoma.
    Jagirdar J; Nonomura A; Patil J; Thor A; Paronetto F
    J Exp Pathol; 1989; 4(1):37-46. PubMed ID: 2550600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Final and future frontiers.
    Friedman SL
    J Hepatol; 2014 Nov; 61(5):969-70. PubMed ID: 25149111
    [No Abstract]   [Full Text] [Related]  

  • 13. The expression of c-myc and c-N-ras in human cirrhotic livers, hepatocellular carcinomas and liver tissue surrounding the tumors.
    Zhang XK; Huang DP; Qiu DK; Chiu JF
    Oncogene; 1990 Jun; 5(6):909-14. PubMed ID: 2163054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functions and therapeutic value of focal adhesion kinase signaling during hepatocellular carcinoma development and progression.
    Alisi A; Balsano C
    Hepatology; 2010 Mar; 51(3):1092-3. PubMed ID: 20017199
    [No Abstract]   [Full Text] [Related]  

  • 15. TGF-beta and hepatocellular carcinoma.
    Bortolami M; Cardin R; Kotsafti A; Farinati F
    Hepatology; 2008 Mar; 47(3):1095; author reply 1095-6. PubMed ID: 18306219
    [No Abstract]   [Full Text] [Related]  

  • 16. [Hepatitis B virus and hepatocellular carcinoma: the track of chromosome X].
    Ratziu V
    Gastroenterol Clin Biol; 1993; 17(4):314-6. PubMed ID: 8393413
    [No Abstract]   [Full Text] [Related]  

  • 17. Carcinogens leave fingerprints.
    Vogelstein B; Kinzler KW
    Nature; 1992 Jan; 355(6357):209-10. PubMed ID: 1309937
    [No Abstract]   [Full Text] [Related]  

  • 18. Refametinib in RAS-mutated hepatocellular cancer.
    Das M
    Lancet Oncol; 2018 Aug; 19(8):e389. PubMed ID: 29983345
    [No Abstract]   [Full Text] [Related]  

  • 19. Oxidative stress and p53 mutations in the carcinogenesis of iron overload-associated hepatocellular carcinoma.
    Marrogi AJ; Khan MA; van Gijssel HE; Welsh JA; Rahim H; Demetris AJ; Kowdley KV; Hussain SP; Nair J; Bartsch H; Okby N; Poirier MC; Ishak KG; Harris CC
    J Natl Cancer Inst; 2001 Nov; 93(21):1652-5. PubMed ID: 11698570
    [No Abstract]   [Full Text] [Related]  

  • 20. A case of hepatocellular carcinoma developed after allogeneic bone marrow transplantation.
    Li L; Hashiyada M; Kume M; Fukumoto M; Yamamoto Y; Funayama M; Yamamoto Y; Fukumoto M
    Pathol Int; 2010 Dec; 60(12):795-7. PubMed ID: 21091839
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.